-
Recent Posts
- Otsuka Announces Phase 3 Results for Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- U.S. FDA APPROVES AURYXIA® (FERRIC CITRATE) TABLETS AS A TREATMENT FOR PEOPLE WITH IRON DEFICIENCY ANEMIA AND CHRONIC KIDNEY DISEASE, NOT ON DIALYSIS
- Pharmalink AB announces the publication in Lancet of Phase 2b trial of Nefecon in primary IgA nephropathy. The data were also presented at the European Renal Association–European Dialysis and Transplant Association (ERA-EDTA) conference (Madrid, Spain)
- Amgen and AbbVie reach a settlement on Humira biosimilar patent litigation
- Merck Provides Update on REVEAL Outcomes Study of Anacetrapib
Recent Comments
Archives
Categories
Meta
Monthly Archives: September 2017
Amgen and AbbVie reach a settlement on Humira biosimilar patent litigation
From Reuters (September 28, 2017) Amgen Inc has reached a settlement with AbbVie Inc that will delay the U.S. launch of Amgen’s cheaper biosimilar version of AbbVie’s cash cow, the blockbuster rheumatoid arthritis drug Humira, until Jan. 31, 2023, the … Continue reading
Posted in M Loghman-Adham, MD
Leave a comment